Pharmaceutical Company Round-up
Page 3 

Cancer Update
Page 4 - News Round-up
Page 6 - Feature Analysis: Targeted therapy cancer brands to achieve sales of over $42 billion by 2017
Page 8 - Opinion: ImClone/BMS/Merck Serono: Erbitux to fortify hold on the head and neck cancer market 
Page 9 - Opinion: Eli Lilly: Alimta receives US green light for lung cancer 
Page 10 - Opinion: Genentech/Roche: disappointing data may not spell the end for Avastin/Tarceva combination
Page 11 - Opinion: GlaxoSmithKline: new data suggest potential for Tykerb indication expansion

Cardiovascular Update
Page 12 - News Round-up

Central Nervous System Update
Page 14 - News Round-up
Page 16 - Opinion: MediciNova: promising MS drug remains in the shop window

IDI Update
Page 17 - News Round-up
Page 19 - Opinion: Sanofi-Aventis: Nasacort catches up with competitors
Page 20 - Opinion: Merck & Co: strengthens osteoporosis pipeline amid falling Fosamax sales 
Page 21 - Opinion: Centocor/Johnson & Johnson: SONIC trial results support Remicade

Infectious Diseases Update
Page 22 - News Round-up
Industry Update
Page 24 - Feature Analysis: Key decision makers will shape the biosimilars landscape
Page 26 - Feature Analysis: Battle for HIV drug market share getting fiercer
Page 28 - Feature Analysis: Opportunity knocks for big pharmaceutical companies in the credit crunch
Page 31 - Opinion: Sanofi-Aventis: persisting in Zentiva bid


Company Spotlight
Page 32 - Pfizer

Biotechnology Update
Page 38 - News Round-up
Page 40 - Feature Analysis: Barack Obama's stance on STEM: a big win for life science research and IT
Page 42 - Opinion: Biosimilars: US presidential candidates pledge support
Page 43 - Opinion: Amgen/Wyeth/Takeda: new data to boost Enbrel's position

Biotechnology Company Spotlight
Page 44 - Neose Technologies

Further Reading
Page 50

Index
Page 51 - Pharma companies
Page 51 - Biotech companies
Page 52 - Key drugs